Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARB-001467 in Chronic HBV
NCT02631096Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Dec 2015
- Primary completion
- May 2018
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of ARB-1467 in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Started Dec 2015; status: completed.
02
Drugs
ARB-1467
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02631096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631096.